SpliSense
Biotechnology company developing inhaled therapies for genetic diseases, focusing on Cystic Fibrosis.
About
SpliSense is a biotechnology company developing transformative RNA-based treatments for pulmonary diseases. Their innovative therapies utilize Antisense Oligonucleotides (ASOs) to restore and modify protein functionality, targeting the root cause of conditions like Cystic Fibrosis and Muco-Obstructive Pulmonary Diseases. Teams look it up for Healthcare, Lung, Treatment.
Frequently asked
What does SpliSense do?
SpliSense is a Healthcare company that offers Hardware, Software. Teams look it up for Lung, Treatment, Biotech. It is based in Rehovot, Israel and was founded in 2017. Public records show about 16 people and $29M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has SpliSense raised?
SpliSense has raised a total of $29M in funding. The most recent round on record is Series B.
Where is SpliSense headquartered?
SpliSense is headquartered in Rehovot, Israel.
When was SpliSense founded?
SpliSense was founded in 2017.
What industry does SpliSense operate in?
SpliSense operates in Healthcare, Lung, Treatment, Biotech, Cystic Fibrosis.
How many employees does SpliSense have?
SpliSense has approximately 16 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.